Literature DB >> 10411927

CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma.

D Mumberg1, P A Monach, S Wanderling, M Philip, A Y Toledano, R D Schreiber, H Schreiber.   

Abstract

CD4(+) T cells can eliminate tumor cells in vivo in the absence of CD8(+) T cells. We have CD4(+) T cells specific for a MHC class II-restricted, tumor-specific peptide derived from a mutant ribosomal protein expressed by the UV light-induced tumor 6132A-PRO. By using neutralizing mAb specific for murine IFN-gamma and adoptive transfer of CD4(+) T cells into severe combined immunodeficient mice, we show that anti-IFN-gamma treatment abolishes the CD4(+) T cell-mediated rejection of the tumor cells in vivo. The tumor cells were MHC class II negative, and IFN-gamma did not induce MHC class II expression in vitro. Therefore, the tumor-specific antigenic peptide must be presented by host cells and not the tumor cells. Tumor cells transduced to secrete IFN-gamma had a markedly reduced growth rate in severe combined immunodeficient mice, but IFN-gamma did not inhibit the growth of the tumor cells in vitro. Furthermore, tumor cells stably expressing a dominant-negative truncated form of the murine IFN-gamma receptor alpha chain, and therefore insensitive to IFN-gamma, nevertheless were rejected by the adoptively transferred CD4(+) T cells. Thus, host cells, and not tumor cells, seem to be the target of IFN-gamma. Together, these results show that CD4(+) T cells can eliminate IFN-gamma-insensitive, MHC class II-negative cancer cells by an indirect mechanism that depends on IFN-gamma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10411927      PMCID: PMC17568          DOI: 10.1073/pnas.96.15.8633

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection.

Authors:  A Knuth; T Wölfel; E Klehmann; T Boon; K H Meyer zum Büschenfelde
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

2.  Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins.

Authors:  A D Luster; J C Unkeless; J V Ravetch
Journal:  Nature       Date:  1985 Jun 20-26       Impact factor: 49.962

3.  The activation of L3T4+ helper T cells assisting the generation of anti-tumor Lyt-2+ cytotoxic T lymphocytes: requirement of Ia-positive antigen-presenting cells for processing and presentation of tumor antigens.

Authors:  A Kosugi; T Yoshioka; T Suda; H Sano; Y Takahama; H Fujiwara; T Hamaoka
Journal:  J Leukoc Biol       Date:  1987-12       Impact factor: 4.962

4.  Multiple tumour-specific antigens expressed on a single tumour cell.

Authors:  R D Wortzel; C Philipps; H Schreiber
Journal:  Nature       Date:  1983 Jul 14-20       Impact factor: 49.962

5.  Presence on a human melanoma of multiple antigens recognized by autologous CTL.

Authors:  B Van den Eynde; P Hainaut; M Hérin; A Knuth; C Lemoine; P Weynants; P van der Bruggen; R Fauchet; T Boon
Journal:  Int J Cancer       Date:  1989-10-15       Impact factor: 7.396

6.  Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells.

Authors:  P L Ward; H Koeppen; T Hurteau; H Schreiber
Journal:  J Exp Med       Date:  1989-07-01       Impact factor: 14.307

7.  Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies.

Authors:  H M Cherwinski; J H Schumacher; K D Brown; T R Mosmann
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

8.  Mechanisms of syngeneic tumor rejection. Susceptibility of host-selected progressor variants to various immunological effector cells.

Authors:  J L Urban; R C Burton; J M Holland; M L Kripke; H Schreiber
Journal:  J Exp Med       Date:  1982-02-01       Impact factor: 14.307

9.  Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells.

Authors:  P D Greenberg; D E Kern; M A Cheever
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

10.  Highly malignant tumor variants retain tumor-specific antigens recognized by T helper cells.

Authors:  C Van Waes; J L Urban; J L Rothstein; P L Ward; H Schreiber
Journal:  J Exp Med       Date:  1986-11-01       Impact factor: 14.307

View more
  116 in total

1.  Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules.

Authors:  G Zeng; C E Touloukian; X Wang; N P Restifo; S A Rosenberg; R F Wang
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

Review 2.  Benign autoimmunity to combat malignancy.

Authors:  H J Stauss
Journal:  Clin Exp Immunol       Date:  2001-07       Impact factor: 4.330

3.  CD4+ T cells induce rejection of urothelial tumors after immune checkpoint blockade.

Authors:  Yuji Sato; Jennifer K Bolzenius; Abdallah M Eteleeb; Xinming Su; Christopher A Maher; Jennifer K Sehn; Vivek K Arora
Journal:  JCI Insight       Date:  2018-12-06

Review 4.  Modulation of antitumor responses by dendritic cells.

Authors:  Johannes Vieweg; Andrew Jackson
Journal:  Springer Semin Immunopathol       Date:  2005-01

5.  NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses.

Authors:  Frits van Rhee; Susann M Szmania; Fenghuang Zhan; Sushil K Gupta; Mindy Pomtree; Pei Lin; Ramesh B Batchu; Amberly Moreno; Guilio Spagnoli; John Shaughnessy; Guido Tricot
Journal:  Blood       Date:  2005-01-25       Impact factor: 22.113

Review 6.  IFN-γ: A cytokine at the right time, is in the right place.

Authors:  J Daniel Burke; Howard A Young
Journal:  Semin Immunol       Date:  2019-06-17       Impact factor: 11.130

7.  Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation.

Authors:  Justin Kline; Long Zhang; Lauren Battaglia; Kenneth S Cohen; Thomas F Gajewski
Journal:  J Immunol       Date:  2012-02-06       Impact factor: 5.422

8.  An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR.

Authors:  Maha Ayyoub; Charles S Hesdorffer; Monica Montes; Andrea Merlo; Daniel Speiser; Donata Rimoldi; Jean-Charles Cerottini; Gerd Ritter; Matthew Scanlan; Lloyd J Old; Danila Valmori
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

9.  piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies.

Authors:  Pallavi V Raja Manuri; Matthew H Wilson; Sourindra N Maiti; Tiejuan Mi; Harjeet Singh; Simon Olivares; Margaret J Dawson; Helen Huls; Dean A Lee; Pulivarthi H Rao; Joseph M Kaminski; Yozo Nakazawa; Stephen Gottschalk; Partow Kebriaei; Elizabeth J Shpall; Richard E Champlin; Laurence J N Cooper
Journal:  Hum Gene Ther       Date:  2010-04       Impact factor: 5.695

10.  Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy.

Authors:  C Berlin; D J Kowalewski; H Schuster; N Mirza; S Walz; M Handel; B Schmid-Horch; H R Salih; L Kanz; H-G Rammensee; S Stevanović; J S Stickel
Journal:  Leukemia       Date:  2014-08-05       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.